Physician profile
Steven L Mackey
NPI 1093725517
$17,206.73
in general payments reported to CMS, 2019-2025
35 companies · $1,705 in 2025
The $1,705 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,920 · 2020: $814 · 2021: $1,270 · 2022: $1,814 · 2023: $1,959 · 2024: $1,724 · 2025: $1,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.66 |
| Education | $380.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,287.61 | 2019-2024 | Ilumya |
| Galderma Laboratories, L.P. | $2,587.53 | 2019-2024 | |
| Abbvie INC. | $2,258.93 | 2019-2025 | |
| Janssen Biotech, INC. | $1,027.59 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $906.02 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $795.09 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $785.62 | 2019-2025 | |
| Amgen INC. | $608.61 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $565.17 | 2019-2025 | |
| Leo Pharma INC. | $528.31 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $373.50 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $294.89 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $268.65 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $237.64 | 2022-2025 | Sotyktu |
| Allergan, INC. | $229.02 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $161.97 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $154.05 | 2023-2025 | Nuzyra |
| Incyte Corporation | $148.57 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $123.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.23 | 2022-2025 | Spevigo, Cyltezo |
| Celgene Corporation | $121.16 | 2019 | |
| Genentech USA, INC. | $90.05 | 2023-2025 | Xolair |
| Lilly USA, LLC | $88.76 | 2023-2024 | Taltz |
| Dermavant Sciences, INC. | $87.18 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.32 | 2019-2024 | Cabtreo, Arazlo |
| Organon LLC | $57.72 | 2024-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $51.72 | 2023 | Idacio |
| Sandoz INC. | $43.42 | 2023 | Hyrimoz |
| Strata Skin Sciences, INC. | $31.04 | 2023 | Xtrac |
| Sanofi-Aventis U.S. LLC | $24.98 | 2021 | |
| Merck Sharp & Dohme LLC | $17.20 | 2019 | |
| Journey Medical Corporation | $16.69 | 2022 | |
| Mission Pharmacal Company | $16.31 | 2021 | |
| Almirall LLC | $15.99 | 2019 | |
| Prugen, INC. Pharmaceuticals | $14.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.